生产企业：Rivus Pharmaceuticals, Inc.
HU6 is the lead candidate of Rivus Pharmaceuticals, a potential best-in-class oral therapeutic for MASH (metabolic dysfunction-associated steatohepatitis), currently advancing in the Phase 2 AMPLIFY trial.
HU6 is the lead candidate of Rivus Pharmaceuticals, a potential best-in-class oral therapeutic for MASH (metabolic dysfunction-associated steatohepatitis), currently advancing in the Phase 2 AMPLIFY trial.
HU6 is being developed for the treatment of MASH (metabolic dysfunction-associated steatohepatitis), currently in Phase 2 clinical trials (AMPLIFY trial).
共 1 项相关疾病
